Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Determination of Amifostine Levels During Radiation Therapy

This study has been completed.
Sponsor:
Information provided by:
University of Iowa
ClinicalTrials.gov Identifier:
NCT00286611
First received: January 31, 2006
Last updated: June 9, 2008
Last verified: June 2008
  Purpose

Currently, there are no published methods for easily determining the level of amifostine in the blood or saliva. A method has been developed within the Department of Radiation Oncology by Drs. Douglas Spitz and Gurminder Sidhu, within the Spitz Lab. This method has been tested using both animal sampling and expired blood (obtained from DeGowin blood center) mixed with amifostine.

If the method proves successful, it could then be used as a tool to quantify blood and salivary amifostine levels and possibly correlate them to treatment efficacy or limiting adverse events using amifostine. A better method of treatment, either increasing the efficacy of amifostine or reducing its unwanted side effects, could then be developed.


Condition Intervention
Cancer
Procedure: Blood and salivary sampling of amifostine

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Serial Blood and Salivary Sampling for Validation of Quantitative Amifostine Assays

Resource links provided by NLM:


Further study details as provided by University of Iowa:

Enrollment: 13
Study Start Date: October 2004
Study Completion Date: May 2008
Groups/Cohorts Assigned Interventions
Amifostine
Those individuals enrolled who have received amifostine as part of standard care.
Procedure: Blood and salivary sampling of amifostine
Sampling of blood and saliva to test for amifostine levels.

Detailed Description:

Currently, there are no published methods for easily determining the level of amifostine in the blood or saliva. A method has been developed within the Department of Radiation Oncology by Drs. Douglas Spitz and Gurminder Sidhu, within the Spitz Lab. This method has been tested using both animal sampling and expired blood (obtained from DeGowin blood center) mixed with amifostine.

If the method proves successful, it could then be used as a tool to quantify blood and salivary amifostine levels and possibly correlate them to treatment efficacy or limiting adverse events using amifostine. A better method of treatment, either increasing the efficacy of amifostine or reducing its unwanted side effects, could then be developed.

Amifostine is an FDA-approved medication that protects the lining of the mucous membranes of the head and neck when radiation treatments are given. Normally, amifostine is injected into a vein causing side effects of nausea, vomiting and low blood pressure. The amifostine can reduce radiation side effects but does not remove them completely.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cancer patients receiving amifostine as a part of their standard cancer therapy.

Criteria

Inclusion Criteria:

  • Ability to understand and willingness to sign a written informed consent document.
  • Receiving radiation treatment at University of Iowa Hospitals and Clinics.
  • Voluntarily elected to receive amifostine during treatment

Exclusion Criteria:

  • none
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00286611

Locations
United States, Iowa
University of Iowa Department of Radiation Oncology
Iowa City, Iowa, United States, 52242
Sponsors and Collaborators
University of Iowa
Investigators
Principal Investigator: John M. Buatti, M.D. University of Iowa Hospitals & Clinics
Study Director: Douglas R. Spitz, Ph.D. Carver College of Medicine University of Iowa
  More Information

No publications provided

Responsible Party: John Buatti, M.D., Department of Radiation Oncology
ClinicalTrials.gov Identifier: NCT00286611     History of Changes
Other Study ID Numbers: 200406002
Study First Received: January 31, 2006
Last Updated: June 9, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by University of Iowa:
Amifostine

Additional relevant MeSH terms:
Amifostine
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Radiation-Protective Agents

ClinicalTrials.gov processed this record on November 24, 2014